New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 28, 2013
16:30 EDTAMRNAmarin believes Vascepa well positioned in triglyceride lowering market
Amarin believes that Vascepa is well positioned to compete in the triglyceride lowering market. This is a large market which, based on market research, Amarin believes is currently underpenetrated due to limitations of existing therapies. Amarin's market research further suggests that clinicians value the data supporting Vascepa in the MARINE indication: in patients with very high (=500 mg/dL) triglyceride levels, Vascepa has been shown to lower triglycerides without increasing bad cholesterol (low-density lipoprotein cholesterol, or LDL-C) and with a tolerability and safety profile similar to placebo. Amarin formally launched Vascepa in the United States on January 28.
News For AMRN From The Last 14 Days
Check below for free stories on AMRN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 31, 2014
11:20 EDTAMRNHigh option volume stocks:
High option volume stocks: AMRN EWT HIMX PTEN URBN MTW VPRT MTH OTEX ZLTQ
09:26 EDTAMRNOn The Fly: Pre-market Movers
Subscribe for More Information
09:11 EDTAMRNAmarin up 12% to $1.78 after positive mention by Adam Feuerstein
Subscribe for More Information
09:10 EDTAMRNAmarin mentioned positively by The Street's Adam Feuerstein
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use